Gelsolin
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Gelsolin
- gelsolin
- Gelsolin
- gelsolin recombinant
- Gelsolin recombinant
- Gelsolin recombinant [WHO-DD]
- gelsolin recombinant who dd
- recombinant human gelsolin
- Recombinant human gelsolin
- Recombinant human plasma gelsolin (Rhu-pGSN)
- recombinant human plasma gelsolin rhu pgsn
- rhu pgsn
- Rhu-pgsn
- Rhu-pGSN
- rhupgsn
- RHUPGSN
- ChEMBL ID
- CHEMBL6068622
- FDA ingredient codes (UNII)
- JBT6SFF5BV
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
Open Targets indications
- Condition identifier
- MONDO_0006502
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
- A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
- Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
- Rhu-pGSN for Severe Covid-19 Pneumonia